Drugs / FIRASTOTUG
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05277402 | Feb → Aug 2022 | — | Adagene Inc | Completed | No outcome recorded |
| Phase 1 | NCT04501276 | Sep 2020 → Jan 2024 | — | Adagene Inc | Completed | No outcome recorded |
| Phase 1 | NCT04111445 | Aug 2019 → Apr 2021 | cancer | Adagene Inc | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FIRASTOTUG | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315007 ↗ |
| Known as | ADG116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05277402 ↗ |
| Modality | Monoclonal antibody | “fully human monoclonal antibody” NCT04111445 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT04111445 ↗ |
| Target | CTLA4 | “specifically binds to human CTLA-4” NCT04111445 ↗ |